Like many of the chemicals and processes powering our bodies, the composition of the microbiome naturally fluctuates ...

A Brooklyn man accused of recording patients in the bathroom of the sleep center where he worked could face time behind bars, ...

By Kamal Choudhury (Reuters) -Alkermes shares tumbled more than 10% on Wednesday after its experimental sleep disorder drug showed weaker-than-expected results, lowering its competitive edge against a ...

Alkermes already has positive results for alixorexton in NT1 from the phase 2 Vibrance-1, while Takeda is developing another ...

Alkermes' experimental drug significantly improved wakefulness and reduced excessive daytime sleepiness in patients with a rare sleep disorder in a mid-stage study, it said on Wednesday. Shares of the ...

Postmenopausal women are especially vulnerable to hypertension, which is a major cardiovascular risk factor. Women ...

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.

The former Long Island sleep center worker who pleaded guilty to secretly recording patients and co-workers in the bathroom ...

Some view health supplements as snake oil. Others don’t. Meanwhile, the nutraceuticals market is growing at a rapid pace and ...

This is the terrifying reality of sleep paralysis. For centuries, people have struggled to explain this scary experience, and this has led to myths of night demons, witches, and even alien abductions.

New research reveals insomnia's deep links to cardiovascular health, urging us to treat it as a core medical issue, not a ...